Home LiteratureArticle Details
PMID: 9652736 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Functional interplay between p53 and E2F through co-activator p300.

Oncogene ·Vol. 16 ·No. 21 ·1998-05-28 ·Pages 2695-710

Lee CW, Sørensen TS, Shikama N, La Thangue NB

Abstract

Both E2F and p53 are sequence specific transcription factors that regulate early cell cycle progression. The pathway of control mediated through E2F governs the transition from G1 into S phase whereas p53 in response to genotoxic stress can facilitate cell cycle arrest or apoptosis. The mechanisms which influence the outcome of p53 induction are not clear, although transcription of the p53 target gene, encoding the cdk-inhibitor p21(Waf1/Cip1), correlates with p53-mediated cell cycle arrest. Here using a combination of biochemical and functional assays we identify p300 as a co-activator required for p53-dependent transcriptional activation of Waf1/Cip1. Furthermore, we show that the cdk-inhibitor p21(Waf1/Cip1) autoregulates in a positive fashion transcription through modulating the activity of the p53/p300 complex, whilst negatively regulating the activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent with a role for p21(Waf1/Cip1) in the autoregulation of p53-dependent transcription, p300 augments the ability of p53 to cause G1 arrest and, conversely, cells undergoing p53-dependent apoptosis are rescued by p300. Thus, our data suggest that the ability of p300 to interact with p53 influences the physiological consequence of p53 activation. From previous studies it is known that cells expressing aberrant levels of E2F-1 can undergo p53-dependent apoptosis. In addition, we find that E2F-1 can cause apoptosis in p53-/- tumour cells and further p300, which also functions as a co-activator for the E2F/DP heterodimer, enhances the apoptotic activity of E2F-1. In conditions where E2F-1 and p53 co-operate in apoptosis E2F-1 can effectively compete for p300, causing a reduction in p53-dependent transcription. Thus, a functional interaction between p300 and either p53 or E2F-1 has a profound impact on early cell cycle progression, specifically in regulating the contrasting outcomes of cell cycle arrest and apoptosis. These results suggest a critical role for p300 in integrating and co-ordinating the functional interplay between the pathways of growth control mediated by E2F and p53.

MeSH Terms
Binding Sites Carrier Proteins Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p21 Cyclins/genetics,metabolism DNA-Binding Proteins E2F Transcription Factors E2F1 Transcription Factor Gene Expression Regulation Humans Nuclear Proteins/genetics,metabolism Recombinant Fusion Proteins/genetics,metabolism Retinoblastoma Protein/pharmacology Retinoblastoma-Binding Protein 1 Trans-Activators Transcription Factor DP1 Transcription Factors/genetics,metabolism,pharmacology Transcription, Genetic Transcriptional Activation Tumor Cells, Cultured Tumor Suppressor Protein p53/genetics,metabolism
Chemicals
CDKN1A protein, human Carrier Proteins Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p21 Cyclins DNA-Binding Proteins E2F Transcription Factors E2F1 Transcription Factor E2F1 protein, human Nuclear Proteins Recombinant Fusion Proteins Retinoblastoma Protein Retinoblastoma-Binding Protein 1 Trans-Activators Transcription Factor DP1 Transcription Factors Tumor Suppressor Protein p53
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Lee C W
Division of Biochemistry and Molecular Biology, University of Glasgow, UK.
Sørensen T S
Shikama N
La Thangue N B
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
1998-05-28
Pages
2695-710
Language
English
Region
England
NLM ID
8711562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com